Drug intelligence / Profile preview

NGN-402

Development stage: Preclinical
Lead developer: Neurogene
Modality: Gene Therapies

Overview

NGN-402 is an investigational AAV-based gene therapy being developed by Neurogene. It is part of Neurogene's pipeline focused on addressing rare neurological diseases. While specific details regarding its mechanism of action or target indication are not publicly available, it is expected to leverage Neurogene's expertise in gene therapy for central nervous system disorders.

Beyond the preview

Go deeper on NGN-402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGN-402.

Explore the full profile